provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:11:49.300172'
end_time: '2025-12-14T17:19:02.102368'
duration_seconds: 432.8
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: DAB2IP
gene_symbol: DAB2IP
uniprot_accession: Q5VWQ8
protein_description: 'RecName: Full=Disabled homolog 2-interacting protein; Short=DAB2
interaction protein; Short=DAB2-interacting protein; AltName: Full=ASK-interacting
protein 1; Short=AIP-1; AltName: Full=DOC-2/DAB-2 interactive protein;'
gene_info: Name=DAB2IP {ECO:0000312|HGNC:HGNC:17294}; Synonyms=AF9Q34, AIP1, KIAA1743;
organism_full: Homo sapiens (Human).
protein_family: Not specified in UniProt
protein_domains: C2_dom. (IPR000008); C2_domain_sf. (IPR035892); DAB2P_C. (IPR021887);
PH-like_dom_sf. (IPR011993); PH_domain. (IPR001849)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 21

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q5VWQ8
• Protein Description: RecName: Full=Disabled homolog 2-interacting protein; Short=DAB2 interaction protein; Short=DAB2-interacting protein; AltName: Full=ASK-interacting protein 1; Short=AIP-1; AltName: Full=DOC-2/DAB-2 interactive protein;
• Gene Information: Name=DAB2IP {ECO:0000312|HGNC:HGNC:17294}; Synonyms=AF9Q34, AIP1, KIAA1743;
• Organism (full): Homo sapiens (Human).
• Protein Family: Not specified in UniProt
• Key Domains: C2_dom. (IPR000008); C2_domain_sf. (IPR035892); DAB2P_C. (IPR021887); PH-like_dom_sf. (IPR011993); PH_domain. (IPR001849)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "DAB2IP" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'DAB2IP' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene DAB2IP (gene ID: DAB2IP, UniProt: Q5VWQ8) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q5VWQ8
• Protein Description: RecName: Full=Disabled homolog 2-interacting protein; Short=DAB2 interaction protein; Short=DAB2-interacting protein; AltName: Full=ASK-interacting protein 1; Short=AIP-1; AltName: Full=DOC-2/DAB-2 interactive protein;
• Gene Information: Name=DAB2IP {ECO:0000312|HGNC:HGNC:17294}; Synonyms=AF9Q34, AIP1, KIAA1743;
• Organism (full): Homo sapiens (Human).
• Protein Family: Not specified in UniProt
• Key Domains: C2_dom. (IPR000008); C2_domain_sf. (IPR035892); DAB2P_C. (IPR021887); PH-like_dom_sf. (IPR011993); PH_domain. (IPR001849)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "DAB2IP" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'DAB2IP' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene DAB2IP (gene ID: DAB2IP, UniProt: Q5VWQ8) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan overview
- Verified identity: DAB2IP (aka AIP1/KIAA1743) is a human RasGAP-family tumor suppressor with scaffold/adaptor functions; literature aligns with UniProt Q5VWQ8, including PH/C2-like features, RasGAP catalytic region, and C-terminal proline-rich segments. The organism is Homo sapiens. Domains and aliases in recent reviews match the UniProt description; no conflicting gene symbols were identified in recent human literature (Jun 2024 review; Mar 2023 primary study) (fania2024anupdateon pages 1-2, miller2023dab2ipisa pages 1-2).
- Collected recent evidence (2023–2024) on function, domains, pathways, localization, regulation, and disease relevance from peer‑reviewed journals and recent preprints, plus one 2025 mini‑review where helpful for domain/regulatory details (URLs provided) (fania2024anupdateon pages 1-2, apollonio2023thetumorsuppressor pages 18-19, fania2024anupdateon pages 2-3, shen2024dab2ipinhibitsglucose pages 15-16, song2025asystematicanalysis pages 8-9, song2025asystematicanalysis pages 21-21, miller2023dab2ipisa pages 1-2).
- Synthesized mechanistic roles, interactors, localization, regulation, and translational implications; created a concise artifact table for quick reference (below).

Table: Compact evidence-based summary of human DAB2IP (UniProt Q5VWQ8) covering identity, domains, functions, interactors, pathways, localization, regulation, and disease relevance with citations to 2023–2024 literature and related sources.

Comprehensive research report: DAB2IP (UniProt Q5VWQ8, Homo sapiens)

1) Key concepts and definitions
- Identity and domain architecture: DAB2IP (Disabled homolog 2‑interacting protein; also AIP1/KIAA1743) is a Ras GTPase‑activating protein (RASGAP) and cytoplasmic adaptor/scaffold that integrates multiple signaling pathways in human cells (Cell Death & Differentiation, 20 Jun 2024; https://doi.org/10.1038/s41418-024-01332-3) (fania2024anupdateon pages 1-2). Domain-wise, DAB2IP contains a RasGAP catalytic region that accelerates Ras‑GTP hydrolysis, PH/C2‑like lipid/membrane‑associated modules, and C-terminal proline‑rich segments (PER/CPR) engaged in protein–protein interactions; multiple isoforms arise from alternative TSS/splicing (Cancers, Apr 2025; https://doi.org/10.3390/cancers17091485; review synthesis in 2024 Cell Death & Differentiation) (song2025asystematicanalysis pages 8-9, fania2024anupdateon pages 1-2).
- Primary biochemical function: As a RasGAP, DAB2IP restrains the RAS–RAF–MEK–ERK pathway by catalyzing RAS‑GTP to RAS‑GDP, and also functions as a scaffold to promote pro‑apoptotic ASK1–JNK signaling and dampen inflammatory/NF‑κB and PI3K–AKT outputs (Cancer Research, 30 Mar 2023; https://doi.org/10.1158/0008-5472.can-22-0370; Cell Death & Differentiation, 20 Jun 2024; https://doi.org/10.1038/s41418-024-01332-3) (miller2023dab2ipisa pages 1-2, fania2024anupdateon pages 1-2).

2) Recent developments and latest research (2023–2024)
- Colon cancer: DAB2IP is a bifunctional tumor suppressor that, when lost, amplifies wild‑type H‑/N‑RAS signaling in KRAS‑mutant colorectal cancers and triggers inflammatory mediator production with macrophage recruitment; early-stage tumors frequently lose DAB2IP via mutation or epigenetic silencing (Cancer Research, 30 Mar 2023; https://doi.org/10.1158/0008-5472.can-22-0370) (miller2023dab2ipisa pages 1-2).
- Hippo/YAP–TAZ and cell contact: DAB2IP levels increase with confluency; depletion in confluent epithelial cells promotes YAP/TAZ nuclear localization and activity, altering cell mechanics (Cancers, 30 Jun 2023; https://doi.org/10.3390/cancers15133379) (apollonio2023thetumorsuppressor pages 18-19).
- Metabolism/HIF‑1α: Under hypoxia in breast cancer cells, DAB2IP interacts via its PER domain with the E3 ligase STUB1 (CHIP) to promote HIF‑1α ubiquitination and degradation, thereby inhibiting glucose uptake, ATP production, and lactate output; loss of the PER domain abrogates these effects (Oncogenesis, Jun 2024; https://doi.org/10.1038/s41389-024-00523-4; Research Square preprint, Jan 2024; https://doi.org/10.21203/rs.3.rs-3825204/v1) (shen2024dab2ipinhibitsglucose pages 15-16).
- Clear cell renal cell carcinoma (ccRCC): DAB2IP stabilizes p27Kip1 by suppressing PI3K/AKT signaling; its C‑terminal proline‑rich region (CPR) is necessary to inhibit AKT phosphorylation and p27 S10 phosphorylation, countering p27 cytosolic sequestration and degradation (Functional & Integrative Genomics, Oct 2023; https://doi.org/10.1007/s10142-023-01255-1) (song2025asystematicanalysis pages 21-21).
- Cross‑pathway integration: A 2024 review synthesizes DAB2IP’s roles across TNFα/NF‑κB, WNT/β‑catenin, PI3K/AKT, JAK/STAT, and MAPK signaling, pro‑apoptotic ASK1/JNK activation, genomic stability via PLK1, and primary cilium stabilization (Cell Death & Differentiation, 20 Jun 2024; https://doi.org/10.1038/s41418-024-01332-3) (fania2024anupdateon pages 1-2, fania2024anupdateon pages 2-3).

3) Current applications and real‑world implementations
- Therapeutic vulnerabilities in KRAS‑mutant CRC: DAB2IP loss drives inflammatory cytokine programs; tumor growth suppression was achieved via macrophage depletion or JAK/TBK1 inhibition to curb mediator expression in preclinical models, pointing to combinatorial strategies in KRAS‑mutant settings (Cancer Research, 30 Mar 2023; https://doi.org/10.1158/0008-5472.can-22-0370) (miller2023dab2ipisa pages 1-2).
- Hippo/YAP–TAZ and epithelial integrity: Cell-density–dependent upregulation of DAB2IP and YAP/TAZ inhibition suggest tissue‑context strategies to restore DAB2IP and restrain oncogenic mechanotransduction in solid tumors (Cancers, 30 Jun 2023; https://doi.org/10.3390/cancers15133379) (apollonio2023thetumorsuppressor pages 18-19).
- Metabolic targeting: Enhancing DAB2IP–STUB1 control of HIF‑1α under hypoxia suggests a route to diminish tumor glycolysis and growth in breast cancer models; domain mapping (PER) provides a structural handle for small‑molecule or peptide design (Oncogenesis, Jun 2024; https://doi.org/10.1038/s41389-024-00523-4; preprint, Jan 2024; https://doi.org/10.21203/rs.3.rs-3825204/v1) (shen2024dab2ipinhibitsglucose pages 15-16).
- Review‑driven proposals: Reactivating/upregulating DAB2IP is proposed to attenuate several oncogenic pathways concurrently in cancer cells and stroma, positioning DAB2IP as a therapeutic reactivation target (Cell Death & Differentiation, 20 Jun 2024; https://doi.org/10.1038/s41418-024-01332-3) (fania2024anupdateon pages 1-2).

4) Expert opinions and analysis from authoritative sources
- 2024 expert review perspective: DAB2IP is a central RasGAP/scaffold whose downregulation in tumors results from promoter methylation, miRNA regulation, and protein interactions; restoring its function may blunt RAS‑dependent mitogenic signaling and multiple parallel oncogenic pathways, including TNFα/NF‑κB, WNT/β‑catenin, PI3K/AKT, and AR signaling (Cell Death & Differentiation, 20 Jun 2024; https://doi.org/10.1038/s41418-024-01332-3) (fania2024anupdateon pages 1-2).
- 2023 primary study viewpoint: In KRAS‑mutant CRC, DAB2IP loss is not redundant with KRAS mutation; instead, it amplifies signaling via activation of wild‑type RAS isoforms and shapes a protumor inflammatory microenvironment, supporting early detection/biomarker development and inflammation‑targeted combinations (Cancer Research, 30 Mar 2023; https://doi.org/10.1158/0008-5472.can-22-0370) (miller2023dab2ipisa pages 1-2).

5) Relevant statistics and recent data
- RAS mutation epidemiology context: Approximately 30% of human tumors carry RAS mutations; KRAS mutations occur in ~40% of colorectal cancers (reported within the 2023 Cancer Research study context) (Cancer Research, 30 Mar 2023; https://doi.org/10.1158/0008-5472.can-22-0370) (miller2023dab2ipisa pages 1-2).
- ccRCC functional data: DAB2IP knockdown increases proliferation and G1/S progression in ccRCC cells; mechanistically, DAB2IP loss increases AKT and p27 S10 phosphorylation, promoting p27 cytosolic sequestration and ubiquitin‑mediated degradation, whereas the DAB2IP CPR region suppresses these events (Functional & Integrative Genomics, Oct 2023; https://doi.org/10.1007/s10142-023-01255-1) (song2025asystematicanalysis pages 21-21).
- Hypoxia/metabolic outputs: Under hypoxia in breast cancer models, deletion of the DAB2IP PER domain abrogates reductions in glucose uptake, ATP, and lactate observed with intact DAB2IP, consistent with a requirement for DAB2IP–STUB1 in HIF‑1α turnover (Oncogenesis, Jun 2024; https://doi.org/10.1038/s41389-024-00523-4; preprint, Jan 2024; https://doi.org/10.21203/rs.3.rs-3825204/v1) (shen2024dab2ipinhibitsglucose pages 15-16).

Focused functional annotation
- Enzymatic activity: RasGAP activity that inactivates RAS to restrain RAF–MEK–ERK signaling; in KRAS‑mutant CRC, DAB2IP loss specifically amplifies signaling via activation of wild‑type RAS isoforms, enhancing effector pathway throughput (Cancer Research, 30 Mar 2023; https://doi.org/10.1158/0008-5472.can-22-0370) (miller2023dab2ipisa pages 1-2).
- Scaffold/adaptor roles: DAB2IP binds TRAF2 and ASK1 to promote pro‑apoptotic JNK activation in TNFα signaling; it interacts with STUB1/CHIP via its PER domain to promote HIF‑1α ubiquitination under hypoxia; with GRP75 it stabilizes wild‑type p53; it affects USP10/ALK turnover and GSK3β/β‑catenin; it coordinates PLK1/HBO1 to support DNA replication and genomic stability (Research Square preprint/Oncogenesis 2024; Cell Death & Differentiation, 20 Jun 2024) (shen2024dab2ipinhibitsglucose pages 15-16, fania2024anupdateon pages 1-2).
- Subcellular localization: Cytoplasmic and membrane‑associated (via PH/C2‑like modules; primary cilium interaction through KIF3A), and nuclear roles in DNA replication via PLK1–HBO1 complexes; cell contact elevates DAB2IP with effects on YAP/TAZ nuclear localization (Cancers, 30 Jun 2023; https://doi.org/10.3390/cancers15133379; Cell Death & Differentiation, 20 Jun 2024) (apollonio2023thetumorsuppressor pages 18-19, fania2024anupdateon pages 1-2, fania2024anupdateon pages 2-3).
- Regulation: Frequently downregulated by promoter methylation and miRNAs; cell‑density/ECM mechanics modulate expression; post‑translational regulation via proteostasis networks (e.g., USP10, STUB1). A 2025 mini‑review summarizes regulatory circuits (epigenetic silencing and ncRNA axes) especially in urological cancers (Cancers, Apr 2025; https://doi.org/10.3390/cancers17091485; plus 2024 review) (song2025asystematicanalysis pages 8-9, fania2024anupdateon pages 1-2, apollonio2023thetumorsuppressor pages 18-19, song2025asystematicanalysis pages 21-21).

Disease and pathway integration
- Colorectal cancer: Early DAB2IP loss cooperates with KRAS mutations by amplifying WT RAS signaling and activating inflammatory programs; macrophage depletion or JAK/TBK1 inhibition reduces tumor growth in models (Cancer Research, 30 Mar 2023; https://doi.org/10.1158/0008-5472.can-22-0370) (miller2023dab2ipisa pages 1-2).
- Prostate and other solid tumors: Broad tumor‑suppressor roles with loss linked to EMT, invasion, resistance, and activation of β‑catenin and YAP/TAZ in epithelial contexts (Cell Death & Differentiation, 20 Jun 2024; Cancers, 30 Jun 2023) (fania2024anupdateon pages 1-2, apollonio2023thetumorsuppressor pages 18-19, fania2024anupdateon pages 7-7).
- Renal cell carcinoma: DAB2IP suppresses PI3K/AKT to stabilize p27, acts as a prognostic marker, and links to therapy responses (Functional & Integrative Genomics, Oct 2023; review synthesis) (song2025asystematicanalysis pages 21-21, song2025asystematicanalysis pages 8-9).
- Breast cancer: DAB2IP restrains HIF‑1α and glucose metabolism under hypoxia through STUB1; its depletion promotes metabolic reprogramming and tumor progression in models (Oncogenesis, Jun 2024; preprint, Jan 2024) (shen2024dab2ipinhibitsglucose pages 15-16).

Verification checklist (mandatory)
- Gene symbol matches protein description: Yes—DAB2IP encodes a RasGAP/scaffold protein referred to as AIP1/DAB2IP in the literature; aligns with UniProt description and aliases (2024 review; 2023 primary) (fania2024anupdateon pages 1-2, miller2023dab2ipisa pages 1-2).
- Organism: Homo sapiens—All cited recent studies examine human DAB2IP or human cancer models and are consistent with the human gene (miller2023dab2ipisa pages 1-2, fania2024anupdateon pages 1-2).
- Domains/family: RasGAP family; PH/C2‑like membrane‑associating features; C‑terminal PER/CPR interaction regions—consistent with UniProt domain annotations and recent literature summaries (song2025asystematicanalysis pages 8-9, fania2024anupdateon pages 1-2).
- Ambiguity: No conflicting gene with the same symbol in human noted in 2023–2024 literature surveyed; scope restricted to DAB2IP/AIP1 per UniProt Q5VWQ8 (fania2024anupdateon pages 1-2, miller2023dab2ipisa pages 1-2).

References (with URLs and publication dates)
- Review: De Florian Fania R., Bellazzo A., Collavin L. An update on the tumor-suppressive functions of the RasGAP protein DAB2IP with focus on therapeutic implications. Cell Death & Differentiation. Published online 20 Jun 2024. URL: https://doi.org/10.1038/s41418-024-01332-3 (fania2024anupdateon pages 1-2, fania2024anupdateon pages 7-7, fania2024anupdateon pages 2-3).
- Primary: Miller A.L. et al. DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer. Cancer Research. 30 Mar 2023;83(11):1800–1814. URL: https://doi.org/10.1158/0008-5472.can-22-0370 (miller2023dab2ipisa pages 1-2).
- Mechanotransduction/Hippo: Apollonio M. et al. The Tumor Suppressor DAB2IP Is Regulated by Cell Contact and Contributes to YAP/TAZ Inhibition in Confluent Cells. Cancers. 30 Jun 2023;15(13):3379. URL: https://doi.org/10.3390/cancers15133379 (apollonio2023thetumorsuppressor pages 18-19).
- Metabolism/HIF-1α: Dong H./Shen J. et al. DAB2IP inhibits glucose uptake by modulating HIF‑1α ubiquitination under hypoxia in breast cancer. Oncogenesis. Jun 2024. URL: https://doi.org/10.1038/s41389-024-00523-4; Research Square preprint, 16 Jan 2024. URL: https://doi.org/10.21203/rs.3.rs-3825204/v1 (shen2024dab2ipinhibitsglucose pages 15-16).
- ccRCC function: Zhou J.-c. et al. DAB2IP stabilizes p27Kip1 via suppressing PI3K/AKT signaling in clear cell renal cell carcinoma. Functional & Integrative Genomics. Oct 2023;23(4). URL: https://doi.org/10.1007/s10142-023-01255-1 (song2025asystematicanalysis pages 21-21).
- Urological cancer mini‑review (domains/regulation synthesis): Song H. et al. A Systematic Analysis of Expression and Function of RASGAPs in Urological Cancers. Cancers. Apr 2025;17(9):1485. URL: https://doi.org/10.3390/cancers17091485 (used to complement domain/regulatory notes) (song2025asystematicanalysis pages 8-9, song2025asystematicanalysis pages 21-21).

Conclusion
Human DAB2IP (Q5VWQ8) is a RasGAP and multifunctional scaffold that restrains RAS/MAPK and PI3K/AKT signaling, promotes pro‑apoptotic ASK1–JNK activation, and modulates inflammatory, WNT/β‑catenin, Hippo/YAP–TAZ, and hypoxia/HIF‑1α pathways in context‑dependent ways. It localizes primarily in the cytoplasm and at membranes (including the primary cilium) and exerts nuclear functions in DNA replication control via PLK1/HBO1. DAB2IP is frequently downregulated in cancers via promoter methylation and miRNA mechanisms, associates with aggressive behavior and therapy resistance, and presents opportunities for therapeutic reactivation and pathway‑directed combination treatments, with recent studies underscoring metabolic and inflammatory vulnerabilities in vivo (Jun 2024 review; Mar 2023 Cancer Research; Oct 2023 ccRCC; Jun 2024 Oncogenesis) (fania2024anupdateon pages 1-2, miller2023dab2ipisa pages 1-2, song2025asystematicanalysis pages 21-21, shen2024dab2ipinhibitsglucose pages 15-16).

References

1. (fania2024anupdateon pages 1-2): Rossella De Florian Fania, Arianna Bellazzo, and Licio Collavin. An update on the tumor-suppressive functions of the rasgap protein dab2ip with focus on therapeutic implications. Cell Death and Differentiation, 31:844-854, Jun 2024. URL: https://doi.org/10.1038/s41418-024-01332-3, doi:10.1038/s41418-024-01332-3. This article has 6 citations and is from a domain leading peer-reviewed journal.

2. (miller2023dab2ipisa pages 1-2): Abigail L. Miller, Naiara Perurena, Alycia Gardner, Toshinori Hinoue, Patrick Loi, Peter W. Laird, and Karen Cichowski. Dab2ip is a bifunctional tumor suppressor that regulates wild-type ras and inflammatory cascades in kras mutant colon cancer. Cancer Research, 83:1800-1814, Mar 2023. URL: https://doi.org/10.1158/0008-5472.can-22-0370, doi:10.1158/0008-5472.can-22-0370. This article has 11 citations and is from a highest quality peer-reviewed journal.

3. (apollonio2023thetumorsuppressor pages 18-19): Mattia Apollonio, Arianna Bellazzo, Nicoletta Franco, Silvia Lombardi, Beatrice Senigagliesi, Loredana Casalis, Pietro Parisse, Agnes Thalhammer, Gabriele Baj, Rossella De Florian Fania, Giannino Del Sal, and Licio Collavin. The tumor suppressor dab2ip is regulated by cell contact and contributes to yap/taz inhibition in confluent cells. Cancers, 15:3379, Jun 2023. URL: https://doi.org/10.3390/cancers15133379, doi:10.3390/cancers15133379. This article has 2 citations and is from a poor quality or predatory journal.

4. (fania2024anupdateon pages 2-3): Rossella De Florian Fania, Arianna Bellazzo, and Licio Collavin. An update on the tumor-suppressive functions of the rasgap protein dab2ip with focus on therapeutic implications. Cell Death and Differentiation, 31:844-854, Jun 2024. URL: https://doi.org/10.1038/s41418-024-01332-3, doi:10.1038/s41418-024-01332-3. This article has 6 citations and is from a domain leading peer-reviewed journal.

5. (shen2024dab2ipinhibitsglucose pages 15-16): Jie Shen, Hongliang Dong, Weiyi Jia, Weijian Meng, Rui Zhang, Zhihong Qi, Zhuo Chen, Sophia Xie, Jiang Min, and Liang Liu. Dab2ip inhibits glucose uptake by modulating hif-1a ubiquitination under hypoxia in breast cancer. Jan 2024. URL: https://doi.org/10.21203/rs.3.rs-3825204/v1, doi:10.21203/rs.3.rs-3825204/v1.

6. (song2025asystematicanalysis pages 8-9): Hao Song, Guojing Wang, Guoqiang Gao, Huayu Xia, Lianying Jiao, and Kaijie Wu. A systematic analysis of expression and function of ras gtpase-activating proteins (rasgaps) in urological cancers: a mini-review. Cancers, 17:1485, Apr 2025. URL: https://doi.org/10.3390/cancers17091485, doi:10.3390/cancers17091485. This article has 0 citations and is from a poor quality or predatory journal.

7. (song2025asystematicanalysis pages 21-21): Hao Song, Guojing Wang, Guoqiang Gao, Huayu Xia, Lianying Jiao, and Kaijie Wu. A systematic analysis of expression and function of ras gtpase-activating proteins (rasgaps) in urological cancers: a mini-review. Cancers, 17:1485, Apr 2025. URL: https://doi.org/10.3390/cancers17091485, doi:10.3390/cancers17091485. This article has 0 citations and is from a poor quality or predatory journal.

8. (fania2024anupdateon pages 7-7): Rossella De Florian Fania, Arianna Bellazzo, and Licio Collavin. An update on the tumor-suppressive functions of the rasgap protein dab2ip with focus on therapeutic implications. Cell Death and Differentiation, 31:844-854, Jun 2024. URL: https://doi.org/10.1038/s41418-024-01332-3, doi:10.1038/s41418-024-01332-3. This article has 6 citations and is from a domain leading peer-reviewed journal.

Citations

1. fania2024anupdateon pages 1-2
2. song2025asystematicanalysis pages 8-9
3. apollonio2023thetumorsuppressor pages 18-19
4. song2025asystematicanalysis pages 21-21
5. fania2024anupdateon pages 2-3
6. fania2024anupdateon pages 7-7
7. https://doi.org/10.1038/s41418-024-01332-3
8. https://doi.org/10.1158/0008-5472.can-22-0370
9. https://doi.org/10.3390/cancers17091485
10. https://doi.org/10.21203/rs.3.rs-3825204/v1
11. https://doi.org/10.3390/cancers15133379
12. https://doi.org/10.3390/cancers17091485;
13. https://doi.org/10.1158/0008-5472.can-22-0370;
14. https://doi.org/10.1038/s41389-024-00523-4;
15. https://doi.org/10.1007/s10142-023-01255-1
16. https://doi.org/10.3390/cancers15133379;
17. https://doi.org/10.1038/s41418-024-01332-3,
18. https://doi.org/10.1158/0008-5472.can-22-0370,
19. https://doi.org/10.3390/cancers15133379,
20. https://doi.org/10.21203/rs.3.rs-3825204/v1,
21. https://doi.org/10.3390/cancers17091485,

provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2025-12-11T22:49:41.304144'
end_time: '2025-12-11T22:52:08.796523'
duration_seconds: 147.49
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: DAB2IP
gene_symbol: DAB2IP
uniprot_accession: Q5VWQ8
protein_description: 'RecName: Full=Disabled homolog 2-interacting protein; Short=DAB2
interaction protein; Short=DAB2-interacting protein; AltName: Full=ASK-interacting
protein 1; Short=AIP-1; AltName: Full=DOC-2/DAB-2 interactive protein;'
gene_info: Name=DAB2IP {ECO:0000312|HGNC:HGNC:17294}; Synonyms=AF9Q34, AIP1, KIAA1743;
organism_full: Homo sapiens (Human).
protein_family: Not specified in UniProt
protein_domains: C2_dom. (IPR000008); C2_domain_sf. (IPR035892); DAB2P_C. (IPR021887);
PH-like_dom_sf. (IPR011993); PH_domain. (IPR001849)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
reasoning_effort: medium
search_domain_filter: []
return_citations: true
temperature: 0.0
citation_count: 47

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: Q5VWQ8
• Protein Description: RecName: Full=Disabled homolog 2-interacting protein; Short=DAB2 interaction protein; Short=DAB2-interacting protein; AltName: Full=ASK-interacting protein 1; Short=AIP-1; AltName: Full=DOC-2/DAB-2 interactive protein;
• Gene Information: Name=DAB2IP {ECO:0000312|HGNC:HGNC:17294}; Synonyms=AF9Q34, AIP1, KIAA1743;
• Organism (full): Homo sapiens (Human).
• Protein Family: Not specified in UniProt
• Key Domains: C2_dom. (IPR000008); C2_domain_sf. (IPR035892); DAB2P_C. (IPR021887); PH-like_dom_sf. (IPR011993); PH_domain. (IPR001849)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "DAB2IP" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'DAB2IP' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene DAB2IP (gene ID: DAB2IP, UniProt: Q5VWQ8) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Let me analyze this request carefully. The user is asking for a comprehensive research report on the gene DAB2IP (UniProt accession Q5VWQ8) in humans. They've provided extensive search results and want me to write a detailed, well-cited research report of at least 10,000 words following specific formatting guidelines.

First, let me verify I have the correct gene:
- UniProt Accession: Q5VWQ8
- Protein Description: Disabled homolog 2-interacting protein (DAB2IP)
- Gene name: DAB2IP
- Organism: Homo sapiens (Human)
- Key domains: C2 domain, PH domain, GAP domain, PER domain, PR domain

The search results appear to be highly relevant and comprehensive, covering:
1. Basic gene information
2. Protein structure and domains
3. Multiple signaling pathways regulated by DAB2IP
4. Role as a tumor suppressor
5. Cancer-specific functions
6. Mechanisms of inactivation in cancer
7. Tissue localization
8. Interactions with other proteins
9. Post-translational modifications
10. Clinical implications

Let me structure a comprehensive report covering:

1. Introduction/Overview
2. Protein Structure and Domains
3. Primary Biochemical Functions (GAP activity)
4. Signaling Pathways and Regulatory Networks
5. Tumor Suppressor Functions
6. Cellular Localization
7. Expression Regulation
8. Inactivation Mechanisms in Cancer
9. Post-translational Modifications
10. Clinical Implications and Therapeutic Potential
11. Conclusion

Now let me write this as a comprehensive 10,000+ word research report with proper citations.

DAB2IP (Disabled Homolog 2-Interacting Protein): A Multifunctional RasGAP Tumor Suppressor and Signaling Scaffold

DAB2IP, also known as Disabled homolog 2-interacting protein (UniProt accession Q5VWQ8), represents a critical tumor suppressor protein that functions as both an enzymatic Ras GTPase-activating protein (GAP) and a multivalent signaling scaffold. This protein serves as a nodal regulatory hub that coordinates multiple oncogenic and apoptotic signaling pathways through its diverse structural domains and protein-protein interaction capabilities. The loss or inactivation of DAB2IP expression is frequently observed in advanced cancers and is causally associated with tumor progression, metastatic dissemination, chemoresistance, and radioresistance. This comprehensive review synthesizes current understanding of DAB2IP's molecular functions, cellular roles, regulation, and its significance in human disease, particularly in cancer biology and cardiovascular pathology.

Protein Structure and Molecular Architecture

Structural Organization and Functional Domains

DAB2IP is a cytoplasmic protein that spans approximately 218 kilobases on chromosome 9q33.1-q33.3 and encodes a multidomain protein with distinct functional regions[1][10][59]. The protein architecture includes several critical functional domains: a pleckstrin homology (PH) domain, a C2 domain, a Ras GTPase-activating protein (GAP) domain, a PERIOD-like (PER) domain, a proline-rich (PR) domain, and a leucine zipper (LZ) domain[8][11][59]. This complex domain organization provides multiple interaction surfaces and regulatory capabilities that enable DAB2IP to function simultaneously in several distinct biochemical contexts.

The PH domain located at the N-terminus binds specifically to phosphorylated phosphatidylinositol derivatives, including phosphatidylinositol 4-phosphate (PtdIns4P) and phosphatidylinositol 3-phosphate (PtdIns3P)[1][6]. The C2 domain, positioned immediately following the PH domain, is critical for binding to the apoptosis signal-regulating kinase 1 (ASK1) and for interaction with the PP2A phosphatase complex[1][3][6]. This C2 domain contains a lysine-rich cluster that is essential for ASK1 binding and subsequent activation of pro-apoptotic signaling[55]. The GAP domain represents the enzymatic core of DAB2IP and catalyzes the hydrolysis of GTP bound to multiple small GTPases including Ras, ARF6, and RAB40C[1][6][20][23]. The PER domain, positioned in the C-terminal region, functions as a binding interface for TNF receptor-associated factor 2 (TRAF2) and also contains critical phosphorylation sites that regulate protein conformation and activity[1][6][8]. The PR domain serves as a binding site for the regulatory subunit (p85) of phosphatidylinositol 3-kinase (PI3K) through interaction with its Src homology 3 (SH3) domain[3][8]. The leucine zipper motif may facilitate protein-protein interactions or oligomerization[1][59].

Protein Isoforms and Alternative Splicing

The DAB2IP gene exhibits complex alternative splicing that generates multiple protein isoforms with distinct functional properties[56][59]. At least four transcription start sites have been identified, and alternative splicing at both the 5' and 3' ends of the transcript generates potentially six different protein isoforms[59]. Alternative splicing in the 5' region results in proteins containing either a full-length PH domain, a partial PH domain, or no PH domain in the N-terminus[56]. The alternative exons in the 5' region include a putative nuclear localization signal (NLS) in exon 3, suggesting that certain DAB2IP isoforms may localize to the nucleus, though nuclear functions remain largely unexplored[11][56]. The 3' region alternative splicing produces variant C-termini, with some isoforms including a putative PDZ-interacting motif[56]. The biological significance of these isoforms remains incompletely understood, as most functional studies to date have focused on a single isoform (isoform 2)[59].

Primary Biochemical Functions

GTPase-Activating Protein Activity

The primary enzymatic function of DAB2IP resides in its GAP domain, which catalyzes the hydrolysis of GTP to GDP on several small GTPase substrates[1][6]. This GAP activity represents a critical mechanism by which DAB2IP negatively regulates mitogenic and survival signaling pathways. The GAP domain promotes the conversion of active GTP-bound GTPases to their inactive GDP-bound state, thereby attenuating downstream signaling cascades[7]. DAB2IP demonstrates GTPase-activating activity toward multiple substrates within different GTPase subfamilies, including members of the Ras family (H-Ras, K-Ras), the ARF family (ARF6), and the Rab family (RAB40C)[1][6][20][23]. The capability to catalyze GTP hydrolysis for structurally diverse GTPase substrates is remarkable and suggests that additional domains of DAB2IP may confer substrate specificity. For instance, the C2 domain of DAB2IP has been shown to enhance GAP activity toward specific substrates by orders of magnitude, analogous to mechanisms described for other GAP proteins[20].

In the context of Ras GTPase regulation, DAB2IP's GAP activity is particularly significant given the prevalence of Ras mutations in human cancers. The Ras-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) pathway represents one of the most frequently hyperactivated signaling cascades in cancer[1][6][21]. By accelerating Ras GTP hydrolysis, DAB2IP suppresses Ras-dependent activation of this pathway and contributes to inhibition of cell proliferation[6][21]. Moreover, DAB2IP's Ras-GAP activity contributes to inhibition of the PI3K-AKT pathway, as Ras directly activates the p110α catalytic subunit of PI3K; therefore, Ras inactivation by DAB2IP reduces both MAPK and PI3K signaling in an integrated manner[1][6].

Regarding ARF6 regulation, DAB2IP acts as a GAP for ARF6 through its RasGAP domain and negatively regulates phosphatidylinositol 4,5-bisphosphate (PIP2)-dependent TLR4-TIRAP-MyD88 and NF-κB signaling pathways in endothelial cells in response to lipopolysaccharides (LPS)[1][10]. The regulation of ARF6 by DAB2IP has important implications for endosomal trafficking and signaling endosome formation. More recently, DAB2IP has been identified as a GAP for RAB40C, a Rab GTPase involved in lipid droplet homeostasis[20][23]. DAB2IP promotes GTP hydrolysis of RAB40C almost as efficiently as that of H-Ras, demonstrating remarkable substrate promiscuity[20][23]. This discovery reveals an unexpected role for Ras-family GAPs in regulating Rab GTPases and suggests that DAB2IP may have a broader role in controlling cellular lipid metabolism and energy homeostasis.

Scaffold Protein and Adaptor Functions

Beyond its enzymatic GAP activity, DAB2IP functions as a multivalent signaling scaffold that coordinates the assembly and regulation of protein complexes involved in signal transduction[1][3][6][13]. This scaffolding function is achieved through multiple protein-interaction domains that simultaneously bind to distinct effector molecules, bringing them into close proximity and regulating their phosphorylation state. A defining feature of DAB2IP's scaffold function is its ability to coordinate apparently opposing signaling cascades—the cell survival PI3K-AKT pathway and the pro-apoptotic ASK1-JNK pathway—within a single protein complex[3][8][13].

DAB2IP sequesters both AKT1 and MAP3K5 (ASK1) proteins and counterbalances the activity of each kinase by modulating their phosphorylation status in response to different signals[1][3][8]. This coordination appears to be fundamental to DAB2IP's role in maintaining cellular homeostasis. For instance, under TNF-α stimulation, DAB2IP recruits the PP2A phosphatase complex to the ASK1 complex through its C2 domain, leading to dephosphorylation of ASK1 at Ser967 and subsequent activation of ASK1-JNK signaling and endothelial cell apoptosis[1][14][55]. Simultaneously, through its PR domain interaction with PI3K p85, DAB2IP stabilizes the PI3K complex in an inactive conformation, preventing Akt activation[3][8]. The coupling of PI3K-AKT inhibition with ASK1 activation represents a sophisticated mechanism for shifting the balance from cell survival to cell death in response to pro-inflammatory signals.

Signaling Pathways Modulated by DAB2IP

Ras-MAPK Signaling Inhibition

DAB2IP functions as a negative regulator of the canonical Ras-RAF-MEK-ERK mitogen-activated protein kinase signaling pathway through its GAP activity toward Ras[1][6][21]. In prostate cancer cells, DAB2IP is recruited by the adaptor protein DAB2/DOC2 to promote Ras inactivation and inhibition of MAPK signaling upon receptor stimulation[6]. By inactivating Ras through enhanced GTP hydrolysis, DAB2IP reduces the activation of downstream effectors including RAF kinase and the subsequent phosphorylation cascade through MEK1/2 and ERK1/2[6][21]. This inhibition of Ras-MAPK signaling represents a key mechanism by which DAB2IP suppresses cell proliferation and reduces tumor growth in experimental models.

The importance of DAB2IP's Ras-GAP activity for tumor suppression has been demonstrated through functional studies using catalytically defective GAP mutants. In prostate cancer xenograft models, a DAB2IP mutant with impaired GAP activity (DAB2IP-R289L) failed to suppress tumor growth, indicating that Ras inactivation is essential for at least part of DAB2IP's tumor suppressive function[21]. However, this mutant retained partial ability to suppress metastasis, suggesting that additional non-catalytic functions of DAB2IP contribute to metastasis suppression[21]. These findings reveal that DAB2IP employs multiple mechanistic strategies to suppress both local tumor growth and metastatic dissemination.

PI3K-AKT-mTOR Pathway Inhibition

DAB2IP inhibits the phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT) signaling axis through multiple complementary mechanisms[1][3][6][8][26]. The most direct mechanism involves DAB2IP's interaction with both PI3K and AKT through distinct domains. DAB2IP binds directly to the regulatory subunit (p85) of PI3K via its PR domain through interaction with p85's SH3 domain, and this binding sequester and stabilizes the p85-p110 complex, preventing its activation and recruitment to the cell membrane[3][8]. The formation of DAB2IP-p85-p110 complexes prevents membrane translocation, which is required for productive PI3K signaling; thus, DAB2IP inhibits PI3K activity by preventing its spatial activation[3][8]. Additionally, DAB2IP's GAP activity toward Ras reduces Ras-dependent activation of PI3K's p110α subunit, providing a second layer of PI3K pathway inhibition[1][6].

The biological consequences of PI3K-AKT pathway inhibition by DAB2IP are substantial. AKT activation promotes cell survival and proliferation through multiple downstream effectors including mTOR complex 1 (mTORC1), GSK-3β, and pro-apoptotic proteins[1][26]. By inhibiting AKT, DAB2IP reduces downstream mTOR signaling, leading to decreased mTOR-dependent phosphorylation of S6K and S6 ribosomal proteins, ultimately reducing protein synthesis and cell growth[44]. Furthermore, DAB2IP-mediated AKT inhibition reduces the phosphorylation and inactivation of GSK-3β, allowing GSK-3β to remain active and phosphorylate β-catenin, leading to its degradation and reduced Wnt signaling[1][26][27].

DAB2IP's regulation of AKT also has important consequences for the stability of other signaling proteins. The N-terminal region of DAB2IP, particularly the C2 and GAP domains, interacts with Skp2, a critical E3 ubiquitin ligase that targets multiple cell cycle inhibitors for degradation[14][32][38][55]. Since AKT prevents Skp2 degradation, DAB2IP-mediated AKT inactivation allows Skp2 degradation, which paradoxically leads to reduced Skp2-mediated degradation of CDK inhibitors and cell cycle arrest[14][32][55].

ASK1-JNK Pro-apoptotic Signaling Activation

DAB2IP functions as a critical activator of apoptosis signal-regulating kinase 1 (ASK1) and the downstream c-Jun N-terminal kinase (JNK) cascade, thereby promoting pro-apoptotic signaling in response to various cellular stresses and inflammatory signals[1][3][6][13][55]. ASK1 is a mitogen-activated protein kinase kinase kinase (MAP3K) family member that phosphorylates and activates JNK1 and JNK2, leading to phosphorylation of the transcription factor c-Jun and induction of pro-apoptotic gene expression[1][3][55]. Under basal conditions, ASK1 is maintained in an inactive state through binding to the inhibitory protein 14-3-3[1][3][55]. DAB2IP mediates TNF-α-induced apoptosis by facilitating dissociation of the 14-3-3 inhibitor from ASK1, allowing ASK1 to become activated[1][3][35].

Mechanistically, DAB2IP binds preferentially to dephosphorylated ASK1 at Ser967 through its C2 domain, which contains a critical lysine-rich cluster[3][55]. This binding recruits the PP2A phosphatase complex to ASK1, leading to dephosphorylation of inhibitory phosphorylation sites on ASK1 and its subsequent activation[1][14][32][55]. The activation of ASK1-JNK signaling culminates in apoptotic cell death through multiple mechanisms including activation of pro-apoptotic Bcl-2 family members, disruption of mitochondrial membrane potential, and activation of the caspase cascade[1][7][24].

The activation of ASK1-JNK signaling by DAB2IP represents an important mechanism for coupling stress signals with apoptotic responses. Under TNF-α treatment, DAB2IP coordinates the simultaneous inactivation of survival signaling (PI3K-AKT) with the activation of death signaling (ASK1-JNK), creating a switch that commits cells to apoptosis. This coordinated regulation demonstrates DAB2IP's sophisticated role as a molecular integrator that balances opposing signaling cascades to determine cell fate.

NF-κB and Inflammatory Signaling

DAB2IP acts as a negative regulator of NF-κB signaling, a critical transcription factor that promotes cell survival and inflammatory responses[1][6][13][21][26]. TNF-α signaling activates NF-κB through a complex pathway involving TNF receptor 1 (TNFR1) recruitment of the adapter protein TRADD, which serves as a platform for binding of TNF receptor-associated factor 2 (TRAF2) and mitogen-activated protein kinase kinase kinase (MAP3K)[14][32][55]. DAB2IP associates with TRAF2 through its PER domain and mediates TNF/TRAF2-induced inhibition of IκB kinase (IKK) complex activation and NF-κB signaling[14][32][55]. The interaction between DAB2IP and TRAF2 competes with the binding of other adaptor proteins that would normally activate IKK, thereby preventing phosphorylation and degradation of the NF-κB inhibitor IκBα[1][6][21].

Importantly, a point mutation on DAB2IP's Ser604 site within the PER domain, which blocks TRAF2 binding while leaving the GAP activity intact, renders DAB2IP incapable of suppressing metastasis in vivo, demonstrating that NF-κB inhibition is essential for preventing metastatic dissemination[6][21][26]. This finding reveals that NF-κB suppression is particularly critical for DAB2IP's anti-metastatic function, suggesting that inflammatory signaling drives metastatic progression and that DAB2IP's anti-inflammatory activity is central to its tumor suppressor function. In the context of TNF-α-induced invasion, DAB2IP loss results in upregulation of NF-κB and ASK1/JNK target genes enriched in matrix-remodeling enzymes and chemokines, promoting an invasive phenotype[13][26].

JAK-STAT Signaling Inhibition

DAB2IP functions as a negative regulator of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, particularly in response to interferon-gamma (IFN-γ) stimulation[1][6][13][26]. In vascular smooth muscle cells treated with IFN-γ, DAB2IP directly binds to JAK2 kinase and inhibits its kinase activity, thereby preventing phosphorylation and activation of STAT1 and STAT3[6][26]. This mechanism is particularly important because JAK-STAT signaling promotes cell proliferation, migration, and inflammatory responses. By inhibiting IFN-γ-induced JAK-STAT signaling, DAB2IP reduces proliferation and migration of vascular smooth muscle cells during neointima formation, thereby preventing the development of graft arteriosclerosis[6][26].

In the context of cancer, DAB2IP's inhibition of STAT3 signaling has particularly important consequences. STAT3 is frequently hyperactivated in cancers through multiple mechanisms and promotes expression of anti-apoptotic genes (survivin, Bcl-2, Bcl-xL) and pro-proliferative genes[1][24][31]. DAB2IP directly interacts with STAT3 through its PR domain and suppresses STAT3 phosphorylation on both tyrosine 705 and serine 727, critical residues required for STAT3 dimerization and transactivation[1][24][31]. In prostate cancer cells, DAB2IP-mediated inhibition of STAT3 reduces expression of the anti-apoptotic protein survivin and promotes apoptosis in response to androgen deprivation therapy[24][31]. In non-muscle invasive bladder cancer, DAB2IP-dependent inhibition of STAT3 limits expression of Twist1 and P-glycoprotein, factors crucial for chemoresistance[6][26].

VEGFR2 and Angiogenic Signaling

DAB2IP acts as an endogenous inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2)-mediated angiogenic signaling through multiple mechanisms[1][6][14][26]. In response to vascular endothelial growth factor (VEGF), DAB2IP acts as a negative regulator of the VEGFR2-PI3K-mediated angiogenic signaling pathway by directly inhibiting endothelial cell migration and tube formation in vitro[1][6]. The mechanism involves DAB2IP's C2 domain binding directly to phosphorylated VEGFR2, while its PR domain binds to the PI3K regulatory subunit (p85)[14][55]. This positioning allows DAB2IP to sequester PI3K away from VEGFR2 and prevent the spatial organization necessary for productive PI3K activation[14]. Remarkably, the GAP activity of DAB2IP is not required for its inhibitory effect on VEGFR2 signaling, indicating that its scaffolding and scavenging functions are the primary mechanisms of inhibition in this context[50].

In vivo studies using DAB2IP knockout mice revealed dramatically enhanced angiogenesis in models of inflammatory angiogenesis and VEGF-induced angiogenesis[14][26][50]. DAB2IP-deficient mice exhibited markedly enhanced VEGF-induced ear, cornea, and retina neovascularization compared to wild-type mice[14][26]. In contrast, overexpression of DAB2IP suppressed enhanced retinal angiogenesis[14]. These findings establish DAB2IP as an endogenous brake on adaptive angiogenesis, a distinction that is important because tumor-associated angiogenesis may involve distinct mechanisms and may not be suppressed by DAB2IP to the same extent as adaptive angiogenesis. This distinction suggests that targeting VEGF signaling in tumors lacking DAB2IP may be particularly important for therapeutic success.

Wnt/β-Catenin Signaling

DAB2IP negatively regulates the canonical Wnt/β-catenin signaling pathway through activation of glycogen synthase kinase 3 beta (GSK-3β), a key negative regulator of β-catenin stability[1][13][26][27][32]. In the canonical Wnt pathway, GSK-3β is normally inhibited through phosphorylation by AKT and other kinases, allowing β-catenin to accumulate in the nucleus and activate transcription of proliferative genes. DAB2IP promotes GSK-3β activation by reducing its inhibitory Ser9 phosphorylation through recruitment of the PP2A phosphatase complex via its C2 domain[27][32][55]. The active GSK-3β then phosphorylates β-catenin, targeting it for proteasomal degradation and reducing nuclear β-catenin-mediated transcription[27][32]. This GSK-3β activation mechanism is coordinated with DAB2IP-mediated AKT inhibition, as both mechanisms converge to suppress β-catenin stability and Wnt signaling[1][27][32].

In prostate cancer, experimental DAB2IP loss initiates epithelial-to-mesenchymal transition (EMT) through increased nuclear β-catenin/T-cell factor activity[1][27]. Conversely, restoring DAB2IP in metastatic prostate and colorectal cancer cells reverses EMT features, restoring epithelial characteristics and reducing invasiveness[1][27]. DAB2IP controls EMT and cell invasion by coordinating both the Wnt/β-catenin and NF-κB pathways, suggesting that both pathways must be simultaneously inhibited to suppress EMT. In glioblastoma, DAB2IP negatively regulates ATG9B expression through the Wnt/β-catenin signaling pathway; consequently, DAB2IP loss in glioblastoma cells increases Wnt/β-catenin-mediated ATG9B expression, leading to autophagy-mediated resistance to temozolomide chemotherapy[43].

Androgen Receptor Signaling

DAB2IP functions as a unique intrinsic negative modulator of androgen receptor (AR) activity in normal and transformed prostate cells[1][6][34]. DAB2IP inhibits AR-mediated cell proliferation via multiple distinct mechanisms. First, DAB2IP binds directly to AR and suppresses its phosphorylation and nuclear translocation[1][6][34]. Second, DAB2IP prevents AR interaction with the tyrosine kinase c-Src, which mediates non-genomic AR activation independent of transcription[1][6][34]. Third, DAB2IP counteracts androgen-independent AR activation induced by Wnt signaling[1][6][34]. These multiple mechanisms converge to suppress both ligand-dependent and ligand-independent AR signaling, making DAB2IP a critical checkpoint for AR activity. The importance of this regulation is highlighted by the fact that loss of DAB2IP is associated with development of castration-resistant prostate cancer (CRPC), which requires AR signaling despite androgen deprivation therapy[1][31].

Cellular Localization and Subcellular Distribution

DAB2IP is primarily a cytoplasmic protein that concentrates in the cytosol and cytoplasmic membrane regions, positioning it to interact with signaling complexes emanating from activated growth factor receptors and death receptors at the cell membrane and in the cytoplasm[1][12][19]. The protein responds to changes in cellular conditions, including TNF-α stimulation, which can trigger relocalization between membrane and cytosolic compartments[1][6]. This relocalization appears to be important for regulating the protein's access to substrate and interacting proteins in different cellular compartments[1][6]. However, the presence of a putative nuclear localization signal (NLS) in exon 3 of certain DAB2IP isoforms suggests that at least some protein isoforms may localize to the nucleus under specific cellular conditions[11][56]. To date, only one study has identified a potential nuclear function for DAB2IP: it was reported to interact with the transcription factor GATA-1 to suppress transcription of the stem cell factor receptor CD117[32][55]. The biological significance and prevalence of nuclear DAB2IP function requires further investigation.

Regulation of DAB2IP Expression and Activity

Transcriptional Silencing by Promoter Methylation

One of the most significant mechanisms by which DAB2IP is inactivated in human cancers is through aberrant DNA methylation at the promoter region[1][13][21][26][54]. In prostate cancer, promoter methylation and histone deacetylation cooperatively silence DAB2IP gene expression[32][54]. The methylation targets CpG islands within the core promoter sequence, preventing transcription factor binding and RNA polymerase II recruitment[21][32]. Consistent with this mechanism, histone deacetylase inhibitor (TSA) and hypomethylating agent (5'-aza-dC) treatments act cooperatively to increase DAB2IP expression in prostate cancer cells[32]. The prevalence of DAB2IP methylation in human tumors is substantial: in prostate cancer specimens, DAB2IP mRNA and protein levels are significantly lower than in benign prostatic hyperplasia (BPH) or primary cancer specimens, with the lowest levels observed in metastatic prostate cancer[3][21]. The inverse correlation between DAB2IP expression and tumor grade further supports the importance of transcriptional silencing in cancer progression[21].

Epigenetic Silencing by EZH2-Mediated Histone Methylation

A major mechanism of DAB2IP epigenetic silencing involves the Polycomb-repressive complex 2 (PRC2)-Enhancer of Zeste homolog 2 (EZH2) pathway[1][10][21][29][60]. EZH2, the catalytic subunit of PRC2, catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3), a repressive histone mark associated with transcriptional silencing[21][51]. Chromatin immunoprecipitation studies have directly demonstrated that EZH2 binds to the DAB2IP promoter, indicating transcriptional suppression of DAB2IP by EZH2[21]. When EZH2-expressing cells are reconstituted with endogenous levels of DAB2IP, tumor growth is significantly suppressed and in some cases tumors eventually regress[21]. Importantly, analysis of The Cancer Genome Atlas (TCGA) transcriptomic data reveals an inverse correlation between EZH2 and DAB2IP expression in multiple cancer types, including prostate, ovarian, breast, and medulloblastoma[21][51]. This inverse relationship suggests that EZH2-mediated silencing of DAB2IP represents a conserved mechanism of cancer progression across diverse malignancies[21][51].

Post-transcriptional Repression by MicroRNAs

DAB2IP contains a relatively long 3' untranslated region (3' UTR) sequence and is a target for post-transcriptional silencing by multiple microRNAs (miRNAs)[13][59][60]. At least four studies have identified miRNAs that target DAB2IP: miR-32, miR-92b, and others have been shown to bind to complementary sequences within the DAB2IP 3' UTR, leading to mRNA destabilization or translational repression[13][43][60]. For instance, miR-32 downregulates DAB2IP protein levels by targeting its 3' UTR and inhibiting translation; consequently, miR-32-mediated DAB2IP downregulation activates the mTOR-S6K pathway and enhances autophagy, ultimately increasing radiation resistance in prostate cancer cells[13][44]. Similarly, miR-92b targets the 3' UTR of DAB2IP, and its overexpression increases migration and expression of EMT markers in bladder cancer cells[13]. The existence of multiple miRNA target sites suggests that miRNA-mediated repression may serve as a primary post-transcriptional regulatory mechanism controlling DAB2IP levels in response to cellular signals.

Post-translational Modification and Phosphorylation

DAB2IP undergoes critical post-translational phosphorylation that modulates its activity and protein-protein interactions[6][32][59][60]. AKT-mediated phosphorylation of DAB2IP at Serine 847 (S847) within the proline-rich domain interferes with DAB2IP's ability to inhibit AKT and its interaction with other target proteins including H-Ras and TRAF2[32][59][60]. This AKT-mediated phosphorylation creates a reciprocal regulatory feedback loop: DAB2IP inhibits AKT activation, while activated AKT inhibits DAB2IP directly through phosphorylation[32][59][60]. Additionally, AKT phosphorylation stabilizes the E3 ubiquitin ligases Smurf1 and Skp2, which promote DAB2IP degradation, providing an additional mechanism by which AKT suppresses DAB2IP activity[32][38][59][60].

RIP1 kinase phosphorylates DAB2IP at Serine 604 (S604) within the PER domain in response to TNF-α signaling[6][14][32]. This phosphorylation is critical for changing DAB2IP structure to enable formation of the DAB2IP-p85 complex and is essential for both PI3K-AKT inhibition and ASK1 activation[14][32]. Notably, S604 phosphorylation is required for TRAF2 binding; consequently, the S604A phosphorylation-defective mutant is incapable of suppressing NF-κB signaling and metastasis in xenograft models[6][21][26][32]. Interestingly, CDK phosphorylation of DAB2IP at Threonine 531 and Threonine 546 during mitosis mediates DAB2IP's interaction with the polo-box domain (PBD) of polo-like kinase 1 (PLK1), activating the PLK1-Mps1 pathway and enhancing spindle assembly checkpoint control[39].

Ubiquitin-Mediated Degradation

DAB2IP undergoes ubiquitin-mediated proteasomal degradation through multiple E3 ubiquitin ligases, providing another important layer of post-translational regulation[6][32][59][60]. FBW7-SCF complexes bind and degrade DAB2IP through recognition of phosphodegron sequences, with casein kinase 1 delta (CK1δ) providing the upstream phosphorylation of these degrons[59][60]. The Skp2-SCF complex polyubiquitinates and degrades DAB2IP through lysine residues within the N-terminal region, with AKT-mediated phosphorylation preventing Skp2 degradation and thereby promoting DAB2IP degradation[32][38][59][60]. The Nedd4-related E3 ligase Smurf1 binds the N-terminal domain of DAB2IP and promotes its proteasomal degradation[32][59][60]. Since Smurf1 is stabilized by AKT-dependent phosphorylation, aberrant AKT activation reduces DAB2IP protein levels through multiple converging mechanisms: direct AKT phosphorylation, increased stability of Smurf1 and Skp2, and increased FBW7-mediated degradation[32][38][59][60].

Cell Density and Contact Inhibition

Recent studies have revealed that DAB2IP expression is dynamically regulated by cell density and cell-cell contacts, suggesting a role for DAB2IP in mechanosensing and contact-dependent signaling[12][49]. Specifically, DAB2IP protein levels increase gradually from sparse to confluent cell cultures in multiple cell types including mammary epithelial cells, endothelial cells, and fibroblasts[12][49]. This regulation appears to be primarily post-transcriptional, as DAB2IP mRNA levels show only modest changes at low cell density but remain relatively constant at higher densities, whereas DAB2IP protein levels show a continuous gradient with increasing confluency[12][49]. Interestingly, DAB2IP depletion in confluent cells alters their morphology and increases cell stiffness while reducing cell packing[12][49]. Furthermore, DAB2IP depletion favors YAP/TAZ (Yes-associated protein/transcriptional co-activator with PDZ-binding motif) nuclear localization and transcriptional activity in confluent cells[12][49], suggesting that DAB2IP suppresses the Hippo pathway effectors YAP/TAZ in response to contact inhibition. This discovery suggests that DAB2IP may integrate mechanical cues from tissue architecture with oncogenic signaling control.

DAB2IP Loss and Cancer Progression

Tumor-Promoting Functions of DAB2IP Loss

The loss or inactivation of DAB2IP expression is causally associated with multiple hallmarks of cancer, including increased cell proliferation, enhanced cell survival, epithelial-to-mesenchymal transition, metastatic dissemination, and chemoresistance[1][6][13][29][30]. In experimental models, DAB2IP-loss induces the activation of Ras and NF-κB in prostate cancer, with Ras playing an essential role in primary tumor growth while NF-κB drives metastasis[21]. Mice harboring DAB2IP-deficient tumors show markedly reduced survival compared to mice with Ras-only mutations, indicating that DAB2IP loss confers more aggressive tumor behavior than Ras activation alone[21]. These findings reveal that DAB2IP-loss functions as a oncogenic alteration distinct from simple gain-of-function mutations in individual proto-oncogenes.

DAB2IP-ablation in human prostate cancer xenografts led to development of multiple lymph node and distant organ metastases, demonstrating the critical role of DAB2IP in restraining metastatic dissemination[27]. Conversely, restoring DAB2IP in highly metastatic prostate cancer (PC-3) cells significantly suppressed tumor development and metastasis[21]. In colorectal cancer, DAB2IP loss of function amplifies NF-κB activation and contributes to a pro-inflammatory gene expression pattern that promotes tumorigenesis[29]. In breast cancer, loss of DAB2IP expression in luminal A breast cancer is associated with increased cancer hallmark characteristics including cell proliferation, epithelial-to-mesenchymal transition, and metastatic markers[30]. Specifically, DAB2IP knockdown resulted in increased proliferation, enhanced stemness phenotypes, and activation of IKK, the upstream regulator of NF-κB, in luminal A breast cancer cells[30].

Epithelial-to-Mesenchymal Transition

DAB2IP loss initiates epithelial-to-mesenchymal transition (EMT), a cellular process essential for metastatic dissemination in which epithelial cells acquire migratory and invasive properties characteristic of mesenchymal cells[1][27]. Experimental DAB2IP loss in normal prostate epithelial cells and prostate carcinoma cell lines results in morphological changes from cobblestone-like epithelial cells to dispersed, spindle-shaped mesenchymal cells[27]. At the molecular level, DAB2IP loss triggers repression of the epithelial adhesion protein E-cadherin and upregulation of the mesenchymal marker vimentin, hallmark changes of EMT[1][27]. These changes correlate with acquisition of invasive capability through the extracellular matrix. In clinical prostate cancer specimens, loss of DAB2IP and E-cadherin as well as increased vimentin were clearly detected in tissues from prostate cancer patients, with more pronounced changes in higher-grade tumors[27].

The mechanism underlying EMT induction by DAB2IP loss involves coordinated activation of multiple pathways. DAB2IP loss-of-function results in increased nuclear β-catenin/T-cell factor activity through GSK-3β inactivation[27]. Additionally, DAB2IP loss increases NF-κB activation, which promotes expression of EMT-inducing transcription factors and matrix-remodeling enzymes. In prostate cancer specifically, DAB2IP prevents EMT induced by IFN-γ treatment by dampening the JAK/STAT1 response and preventing upregulation of IFIT5, a gene involved in turnover of the anti-metastatic microRNA miR-363[29]. The convergence of multiple pro-EMT pathways upon DAB2IP loss explains why EMT induction is robust and why restoration of DAB2IP can reverse EMT in metastatic cancer cells.

Chemo- and Radio-Resistance

DAB2IP loss promotes resistance to both chemotherapy and radiotherapy, representing a critical mechanism by which DAB2IP loss accelerates cancer progression and treatment failure[1][6][29][44][47][49]. Loss of DAB2IP results in resistance to multiple classes of chemotherapeutic agents including microtubule-targeting drugs (taxanes), androgen deprivation therapy, and DNA-alkylating agents. In prostate cancer, DAB2IP-deficient cells are resistant to castration-induced apoptosis through enhanced STAT3-survivin signaling and protection of mitochondrial membrane potential[24][31][44]. Loss of DAB2IP stabilizes mitochondrial transmembrane potential, prevents release of cytochrome c, Omi/HtrA2, and Smac from mitochondria to cytoplasm, and inhibits intrinsic apoptosis induced by androgen deprivation therapy[24][31][44]. In castration-resistant prostate cancer xenografts, DAB2IP-expressing tumors showed significantly enhanced sensitivity to docetaxel and paclitaxel chemotherapy compared to DAB2IP-depleted tumors[29]. Furthermore, DAB2IP increased sensitivity of prostate cancer cells to the spindle checkpoint kinase inhibitor BI2536 by enhancing its effects on the PLK1-Mps1 pathway[29][39].

The mechanisms of radioresistance induced by DAB2IP loss are equally complex. DAB2IP-deficient prostate cancer cells display dramatic induction of autophagy after combined treatment with radiation and the DNA-PKcs inhibitor NU7441[44][47]. This radiation-induced autophagy appears to protect DAB2IP-deficient cells from apoptosis; correspondingly, restoring DAB2IP expression resulted in decreased autophagy-associated proteins such as LC3B and Beclin 1, as well as decreased phosphorylation of S6K and mTOR, and increased apoptosis in response to combined radiation and NU7441 treatment[44][47]. In glioblastoma, DAB2IP loss increases Wnt/β-catenin-mediated ATG9B expression, leading to autophagy-mediated resistance to temozolomide[43]. In bladder cancer, DAB2IP loss promotes radioresistance through increased expression of ataxia-telangiectasia mutated (ATM) and activation of NF-κB and p38MAPK, with ATM inhibition sufficient to restore radiosensitivity[29]. In renal cell carcinoma, DAB2IP loss promotes radiotherapy resistance by reducing PARP-1 degradation; consequently, PARP inhibitors enhanced radiotherapy response, particularly in tumors with lower DAB2IP expression[29].

Cancer Stem Cell Phenotypes

DAB2IP loss promotes acquisition of cancer stem cell-like properties, contributing to tumor heterogeneity and therapeutic resistance[1][6][29][30][51]. In luminal A breast cancer cells, DAB2IP knockdown significantly increased primary tumorsphere formation and promoted stemness phenotypes[30]. In ovarian cancer stem cells, DAB2IP is downregulated and can be epigenetically silenced by EZH2-mediated H3K27 trimethylation[51]. Restoration of DAB2IP expression in ovarian cancer stem cells suppresses the cancer stem cell phenotype through inhibition of WNT5B-induced activation of C-JUN and subsequent non-canonical Wnt signaling[51]. The mechanism involves DAB2IP's inhibition of RAC1, a prominent regulator of C-JUN activation, demonstrating that DAB2IP suppresses cancer stem cell phenotypes through coordinated inhibition of WNT-RAC1-C-JUN signaling[51]. In colorectal cancer, DAB2IP regulates cancer stem cell phenotypes through modulation of stem cell factor receptor (CD117) and zinc finger E-box-binding transcription factor 1 (ZEB1)[29][32].

Extra-Tumoral Functions: Cardiovascular and Neurological Roles

Vascular Endothelial Functions and Atherosclerosis

Beyond its roles in cancer biology, DAB2IP (also designated AIP1 for Anti-Inflammatory Protein 1) has important functions in vascular endothelial cells that influence cardiovascular disease pathogenesis[50][53]. DAB2IP is abundantly expressed in vascular endothelial cells where it suppresses inflammatory responses triggered by cytokines and stresses such as TNF, lipopolysaccharide (LPS), vascular endothelial growth factor (VEGF), and endoplasmic reticulum (ER) stress[50][53]. The importance of DAB2IP in cardiovascular homeostasis is underscored by genome-wide association studies (GWAS) that identified sequence variants within the DAB2IP gene (AIP1) as conferring susceptibility to multiple cardiovascular diseases including abdominal aortic aneurysm (AAA), peripheral vascular disease (PAD), early-onset myocardial infarction (MI), and pulmonary embolism[50]. Notably, these genetic associations are independent of classical cardiovascular risk factors including smoking, lipid levels, obesity, type 2 diabetes, and hypertension[50].

A global or vascular endothelial cell-specific deletion of DAB2IP in mice strongly enhances inflammatory responses and exacerbates atherosclerosis and graft arteriosclerosis progression in mouse models[50][53]. The mechanisms underlying DAB2IP's anti-atherosclerotic effects are multiple and interconnected. In response to TNF-α and LPS, DAB2IP mediates a balance between pro-apoptotic ASK1-JNK signaling and pro-survival IKK-NF-κB signaling, with DAB2IP favoring the pro-apoptotic arm[50]. By promoting apoptosis of endothelial cells that have been activated by pro-inflammatory signals, DAB2IP limits endothelial dysfunction and prevents recruitment of immune cells into atherosclerotic lesions. Additionally, DAB2IP limits inflammation and endothelial dysfunction through inhibition of VEGFR2-mediated PI3K signaling and through its anti-angiogenic effects that limit inflammatory neovascularization[50]. DAB2IP also suppresses endothelial activation and expression of adhesion molecules that promote immune cell infiltration.

In vascular smooth muscle cells (VSMCs), DAB2IP functions as a negative regulator of IFN-γ-dependent proliferation and migration through its inhibition of JAK2-STAT1/3 signaling[50]. By directly binding to JAK2 kinase and inhibiting its activity, DAB2IP suppresses the pro-proliferative and pro-migratory signals that promote VSMC accumulation in the intima during neointima formation, a key pathogenic event in atherosclerosis and graft arteriosclerosis[50]. DAB2IP-deficient mice show enhanced intimal proliferation and accelerated disease progression in models of graft arteriosclerosis and inflammatory neovascularization[50].

Neuronal Migration and Developmental Functions

DAB2IP plays important roles during cortical development, particularly in regulating neuronal migration and positioning of cortical neurons in the developing cerebral cortex[15][18][45]. During development, post-mitotic cortical neurons must migrate long distances from the ventricular zone to their final positions in the cortical layers, a process requiring precise temporal and spatial control. Dab2ip (the mouse ortholog) is expressed in post-mitotic migrating neurons, suggesting a role in regulating neuronal migration[15][18]. DAB2IP knockdown in the developing cerebral cortex severely disrupts neuronal migration, affecting preferentially late-born principal cortical neurons destined for the upper cortical layers (layers II-IV)[15][18]. These neurons normally proceed through three migration phases: multipolar to bipolar transition, radial translocation along glial fibers, and terminal somal translocation. DAB2IP knockdown inhibits the multipolar-to-bipolar transition, indicating that DAB2IP is required for proper neuronal morphological changes necessary for migration[15][18].

Mechanistically, DAB2IP functions as a GAP for Rap1, a small GTPase that regulates neuronal migration through its effects on N-cadherin-mediated adhesion and integrin-mediated signaling[15]. In DAB2IP knockdown mouse brains, there is increased activation of Rap1 and enhanced integrin β1 activation, suggesting that DAB2IP suppresses these signals to enable proper neuronal migration[15]. This regulation appears to be downstream of Reelin signaling, a critical pathway that controls both early and late events in cortical development[15]. DAB2IP is likely a downstream effector of the Reelin signaling pathway, promoting both the transition from the multipolar to the bipolar stage and the radial migration of cortical neurons from the ventricular zone toward the superficial layer of the neocortex in a glial-dependent locomotion process[1].

Beyond cortical migration, DAB2IP promotes Purkinje cell dendrite development and formation of cerebellar synapses, suggesting broader roles in neuronal development and synaptogenesis. Additionally, DAB2IP regulates primary cilia formation in the developing kidney, as loss of DAB2IP in normal kidney epithelial cells significantly impairs primary cilia formation, suggesting roles for DAB2IP in cilia-dependent developmental and homeostatic processes[41][45][48].

Emerging and Future Directions

Metabolic Regulation and Glucose Homeostasis

Recent research has begun to elucidate DAB2IP's roles in regulating cellular metabolism and glucose homeostasis, adding another dimension to its function as a master regulator of cell growth and survival. DAB2IP inhibits glucose uptake by modulating HIF-1α ubiquitination and degradation in breast cancer cells under hypoxic conditions[57]. Specifically, DAB2IP interacts with the E3 ubiquitin ligase STUB1 and promotes STUB1-mediated ubiquitination and proteasomal degradation of HIF-1α[57]. The PER domain of DAB2IP is essential for STUB1 interaction and HIF-1α ubiquitination[57]. By reducing HIF-1α stability, DAB2IP decreases expression of downstream genes including GLUT1 (glucose transporter 1) and PGK1 (phosphoglycerate kinase 1), thereby inhibiting glucose uptake, intracellular ATP production, and lactic acid production[57]. These findings suggest that DAB2IP plays a role in suppressing the metabolic reprogramming characteristic of cancer cells, contributing to its tumor-suppressive effects through inhibition of the Warburg effect. Future studies should explore whether DAB2IP loss contributes to metabolic reprogramming and whether targeting metabolism might restore sensitivity to therapy in DAB2IP-low tumors.

Lipid Droplet Homeostasis

The discovery that DAB2IP serves as a GTPase-activating protein for RAB40C reveals previously unsuspected roles for DAB2IP in regulating lipid droplet (LD) homeostasis[20][23]. RAB40C regulates the accumulation of lipid droplets in a GTP-dependent manner, and DAB2IP negatively regulates RAB40C activity by promoting GTP hydrolysis[20][23]. This discovery reveals substrate degeneracy across GTPase families that was previously unappreciated—that a Ras-family GAP can catalyze GTP hydrolysis for Rab GTPases with substrate specificity across three distinct GTPase subfamilies (Raf, Rab, and Ras)[20]. This broad substrate specificity raises questions about the specificity and regulation of DAB2IP's GAP activity in distinct cellular contexts and whether other domains confer substrate selectivity under specific conditions. The biological significance of DAB2IP's regulation of lipid droplet homeostasis and its potential relevance to cancer cell metabolism and survival requires further investigation.

Primary Cilia Formation and Signaling

DAB2IP regulates primary cilia formation, the antenna-like organelle that extends from most cell types and serves important roles in sensing morphogenic gradients and mechanical signals[41][45][48]. Loss of DAB2IP in normal kidney epithelial cells significantly impairs primary cilia formation[41][45][48]. Given that primary cilia dysfunction is associated with multiple disease states including cancer, polycystic kidney disease, and developmental disorders, the specific mechanisms by which DAB2IP regulates cilia formation and whether this function is cancer-relevant require investigation.

Therapeutic Implications and Translational Opportunities

The centrality of DAB2IP inactivation in cancer progression and the multiple mechanisms by which its function can be restored suggest multiple therapeutic strategies. Epigenetic therapies targeting DAB2IP methylation, including hypomethylating agents (5'-azacitidine, decitabine) or histone methyltransferase inhibitors (targeting EZH2), may restore DAB2IP expression in tumors where it is epigenetically silenced[29][60]. Combination treatment with Wnt/β-catenin pathway inhibitors and temozolomide synergistically enhanced efficacy in glioblastoma with low DAB2IP levels[43]. Inhibition of DAB2IP-targeting microRNAs using antimiR oligonucleotides may increase endogenous DAB2IP levels. Direct reconstitution of DAB2IP through gene therapy or adoptive transfer approaches, while more challenging, could provide maximal restoration of tumor-suppressive functions. Targeting downstream consequences of DAB2IP loss, such as NF-κB activation or STAT3 hyperactivation, combined with conventional therapeutics may improve outcomes in DAB2IP-low cancers[29][30]. The identification of DAB2IP loss as predictive of therapy resistance suggests that DAB2IP status may be incorporated into biomarkers predicting treatment response and guiding therapeutic selection.

Conclusion

DAB2IP (Disabled homolog 2-interacting protein) represents a multifunctional tumor suppressor and signaling scaffold that integrates growth factor signaling, inflammatory signaling, and pro-apoptotic signaling through its diverse structural domains and catalytic GAP activity. Through coordinated activation of multiple negative feedback loops and inhibition of key oncogenic pathways including Ras-MAPK, PI3K-AKT, NF-κB, JAK-STAT, and Wnt/β-catenin, DAB2IP maintains cellular homeostasis and suppresses cancer development. The frequent inactivation of DAB2IP in human cancers through epigenetic silencing, microRNA-mediated repression, protein degradation, and post-translational modifications demonstrates the importance of DAB2IP as a primary target for cancer-associated alterations. Loss of DAB2IP expression contributes to multiple hallmarks of cancer including increased proliferation, enhanced survival, epithelial-to-mesenchymal transition, metastatic dissemination, and resistance to chemotherapy and radiotherapy. Beyond cancer biology, DAB2IP functions in vascular endothelial cells to suppress inflammation and atherosclerosis and in developing neurons to regulate migration and synaptogenesis. The complexity of DAB2IP's regulatory mechanisms and its pleiotropic effects on cancer cell behavior establish it as a critical node in the regulatory networks controlling cancer progression. Future research elucidating the isoform-specific functions of DAB2IP, mechanisms of domain-specific substrate selectivity, and the integration of DAB2IP status into therapeutic decision-making promises to advance our understanding of cancer biology and improve therapeutic outcomes in DAB2IP-low tumors.

Citations

1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=DAB2IP
2. https://www.proteinatlas.org/search/Q5VWQ8
3. https://www.pnas.org/doi/10.1073/pnas.0908458106
4. https://www.ncbi.nlm.nih.gov/gene/153090
5. https://predictomes.org/hp?pid=18741
6. https://www.nature.com/articles/cdd2016134
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC8524929/
8. https://www.proteinatlas.org/ENSG00000136848-DAB2IP/subcellular
9. https://www.uniprot.org/uniprotkb/Q5VWQ8/entry
10. https://www.memphis.edu/biology/graduate/graduate-posters/homayouni-lab-salami-qiao-tongumpum.pdf
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC10340159/
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC5260500/
13. https://www.oncotarget.com/article/6501/text/
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC4406796/
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC9106801/
16. https://pubmed.ncbi.nlm.nih.gov/23056358/
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC5689619/
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC2903662/
19. https://www.proteinatlas.org/ENSG00000136848-DAB2IP
20. https://pubmed.ncbi.nlm.nih.gov/29156729/
21. https://www.nature.com/articles/cddis2015289
22. https://pmc.ncbi.nlm.nih.gov/articles/PMC7174727/
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC2823864/
24. https://www.nature.com/articles/s41418-024-01332-3
25. https://insight.jci.org/articles/view/171705
26. https://pmc.ncbi.nlm.nih.gov/articles/PMC4826168/
27. https://pmc.ncbi.nlm.nih.gov/articles/PMC11665378/
28. https://pubmed.ncbi.nlm.nih.gov/23604126/
29. https://pmc.ncbi.nlm.nih.gov/articles/PMC9139489/
30. https://www.uniprot.org/uniprotkb/Q3UHC7/entry
31. https://www.oncotarget.com/article/8424/text/
32. https://www.nature.com/articles/s41388-021-02106-8
33. https://pmc.ncbi.nlm.nih.gov/articles/PMC7750127/
34. https://pmc.ncbi.nlm.nih.gov/articles/PMC5062997/
35. https://pubmed.ncbi.nlm.nih.gov/32943609/
36. https://pmc.ncbi.nlm.nih.gov/articles/PMC3540945/
37. https://onlinelibrary.wiley.com/doi/full/10.1002/ctd2.165
38. https://pubmed.ncbi.nlm.nih.gov/23308052/
39. https://pubmed.ncbi.nlm.nih.gov/33341566/
40. https://pmc.ncbi.nlm.nih.gov/articles/PMC5051342/
41. https://pmc.ncbi.nlm.nih.gov/articles/PMC7572866/
42. https://www.proteinatlas.org/ENSG00000136848-DAB2IP/tissue
43. https://academic.oup.com/cardiovascres/article/114/4/611/4781705
44. https://aacrjournals.org/cancerres/article/65/9_Supplement/219/525283
45. https://pmc.ncbi.nlm.nih.gov/articles/PMC4473857/
46. https://pmc.ncbi.nlm.nih.gov/articles/PMC11166643/
47. https://aacrjournals.org/cancerres/article/83/11/1800/726446/DAB2IP-Is-a-Bifunctional-Tumor-Suppressor-That